Silence Therapeutics (NASDAQ:SLN – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $75.00 price target on the stock.
Several other research analysts have also commented on the company. Morgan Stanley cut their price objective on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, May 9th. The Goldman Sachs Group dropped their target price on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a research report on Friday, May 9th. Chardan Capital dropped their target price on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, BMO Capital Markets dropped their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.83.
View Our Latest Research Report on Silence Therapeutics
Silence Therapeutics Stock Down 4.7%
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $3.58 million. On average, equities research analysts anticipate that Silence Therapeutics will post -1.77 EPS for the current fiscal year.
Institutional Investors Weigh In On Silence Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new stake in Silence Therapeutics in the fourth quarter worth $26,000. Barclays PLC grew its stake in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after acquiring an additional 2,793 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after acquiring an additional 6,098 shares during the last quarter. Jump Financial LLC purchased a new stake in shares of Silence Therapeutics in the first quarter worth $74,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Silence Therapeutics in the fourth quarter worth $113,000. 98.73% of the stock is owned by hedge funds and other institutional investors.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Read More
- Five stocks we like better than Silence Therapeutics
- How to Capture the Benefits of Dividend Increases
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- Golden Cross Stocks: Pattern, Examples and Charts
- Alphabet Enters a Bull Market: Is It Time to Buy?
- How to Effectively Use the MarketBeat Ratings Screener
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.